An update on the state of knowledge on the COVID-19 pandemic and how this pertains to health including the influence on antiviral strategies to stop the spread of the virus and potential treatments for the disease.
The Oxford vaccine, ChAdOx1 nCoV-19, has demonstrated strong immune responses to COVID-19 in patients, as well as a good safety profile, as the results of the Phase I/II trial are published.
In collaboration with the University of Southampton, Synairgen (both Southampton, UK) have announced positive results from their recent trial of SNG001, a novel protein based COVID-19 drug.
A research team from The Rosalind Franklin Institute, Diamond Light Source, The University of Oxford and Public Health England have engineered nanobodies from llama antibodies that show protective immune effects against SARS-CoV-2.
Differences in lung physiology and immune function in children may lie behind their decreased rates of symptomatic infections, hospitalization and death, according to a study from The University of Texas and Baylor College of Medicine (both TX, USA).
In a collaborative study between the University of South Florida (USF Health; FL, USA) and the University of Arizona College of Pharmacy (AZ, USA), several existing drugs have been identified as potential therapies for COVID-19.
The emergence and global spread of SARS-CoV-2 has prompted scientific study on an unprecedented scale, with an urgent need for…
Researchers have identified a specific change in the SARS-CoV-2 coronavirus spike protein that may increase its transmission, making it more infectious in cell culture.
Researchers at Cedars-Sinai Medical Center have discovered that SARS-CoV-2 can infect human myocardiocytes in vitro. COVID-19 infection can cause heart problems. This study demonstrates that this could be due to direct infection of myocardiocytes by the virus.